A Single Amino Acid Deletion (ΔF1502) in the S6 Segment of CaV2.1 Domain III Associated with Congenital Ataxia Increases Channel Activity and Promotes Ca2+ Influx

Maria Isabel Bahamonde1*, Selma Angélica Serra1*, Oliver Drechsel2,3, Rubayte Rahman2,3, Anna Marcé-Grau4, Marta Prieto1, Stephan Ossowski2,3, Alfons Macaya4†, José M. Fernández-Fernández1‡*

1 Laboratori de Fisiologia Molecular i Canalopaties, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain, 2 Genomic and Epigenomic Variation in Disease Group, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain, 3 Universitat Pompeu Fabra, Barcelona, Spain, 4 Pediatric Neurology Research Group, Vall d’Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain

* These authors contributed equally to this work.
‡ AM and JMF-F are joint senior authors on this work.
* jmanuel.fernandez@upf.edu

Abstract

Mutations in the CACNA1A gene, encoding the pore-forming CaV2.1 (P/Q-type) channel α1A subunit, result in heterogeneous human neurological disorders, including familial and sporadic hemiplegic migraine along with episodic and progressive forms of ataxia. Hemiplegic Migraine (HM) mutations induce gain-of-channel function, mainly by shifting channel activation to lower voltages, whereas ataxia mutations mostly produce loss-of-channel function. However, some HM-linked gain-of-function mutations are also associated to congenital ataxia and/or cerebellar atrophy, including the deletion of a highly conserved phenylalanine located at the S6 pore region of α1A domain III (ΔF1502). Functional studies of ΔF1502 CaV2.1 channels, expressed in Xenopus oocytes, using the non-physiological Ba2+ as the charge carrier have only revealed discrete alterations in channel function of unclear pathophysiological relevance. Here, we report a second case of congenital ataxia linked to the ΔF1502 α1A mutation, detected by whole-exome sequencing, and analyze its functional consequences on CaV2.1 human channels heterologously expressed in mammalian tsA-201 HEK cells, using the physiological permeant ion Ca2+. ΔF1502 strongly decreases the voltage threshold for channel activation (by ~ 21 mV), allowing significantly higher Ca2+ current densities in a range of depolarized voltages with physiological relevance in neurons, even though maximal Ca2+ current density through ΔF1502 CaV2.1 channels is 60% lower than through wild-type channels. ΔF1502 accelerates activation kinetics and slows deactivation kinetics of CaV2.1 within a wide range of voltage depolarization. ΔF1502 also slowed CaV2.1 inactivation kinetic and shifted the inactivation curve to hyperpolarized potentials (by ~ 28 mV). ΔF1502 effects on CaV2.1 activation and deactivation properties seem to be of high physiological relevance. Thus, ΔF1502 strongly promotes Ca2+ influx in response to...
either single or trains of action potential-like waveforms of different durations. Our observations support a causative role of gain-of-function Cαv2.1 mutations in congenital ataxia, a neurodevelopmental disorder at the severe-most end of CACNA1A-associated phenotypic spectrum.

Introduction

The CaV2.1 (P/Q-type) Ca2+ channel, encoded by the CACNA1A gene, is a high-voltage-activated channel composed of a main transmembrane pore-forming subunit (α1A), associated to a disulfide-linked α2δ subunit dimer, and one or more intracellular β subunits (CaV β1–4). The α1A subunit consists of four repeated domains (I–IV) each containing six transmembrane regions (S1–S6) with a voltage sensor (S1–S4) and a pore region (S5, P-loop and S6). The N- and C-terminal regions as well as the large intracellular loops between α1A domains serve as signalling platforms for channel gating regulation processes, which includes the functional interaction with presynaptic proteins such as SNARE proteins of the vesicle docking/fusion machinery [1,2]. Indeed, CaV2.1 channels are localized at presynaptic terminals [3] tightly coupled to neurotransmitter release [1]. Nevertheless, it also presents somatodendritic localization in neurons, thus contributing to the generation of postsynaptic responses, such as neuronal excitability [4–6], gene expression [7], Ca2+ signaling microdomains [8], and neuronal survival [9].

CaV2.1 channels are expressed in all brain areas involved in the pathogenesis of migraine, including the cerebral cortex and nociceptive pathways, and their expression is particularly high in the cerebellum (reviewed in [10,11]). Accordingly, mutations in the CACNA1A gene are linked to familial and sporadic hemiplegic migraine (FHM/SHM), and both episodic and progressive forms of ataxia (reviewed in [11]).

FHM and SHM are rare subtypes of migraine with aura that include hemiparesis during the aura phase [10–12]. Hemiplegic Migraine (HM) mutations in the α1A channel subunit locate around the line pore (S5-P-S6 segments), in the loops connecting S3-S4 or S4-S5 segments and in the S1 and S4 segments of the voltage sensors [11,13,14]. The functional analysis of all HM CACNA1A mutations evaluated so far, both in heterologous expression systems and excitatory neurons from FHM knock-in (KI) mice, revealed an overall gain of CaV2.1 channel function, mainly due to a reduction in the voltage threshold of channel activation [11,15–18]. Further studies in FHM KI mice indicate that such gain-of-channel-function specifically enhances excitatory transmission at cortical synapses to favor initiation and propagation of cortical spreading depression (CSD), an abnormal increase of cortical activity -followed by a long-lasting neuronal suppression wave- that propagates across the cortex and triggers the aura and migraine itself [10–12,16–20].

Episodic ataxia type 2 (EA2), is a rare neurological disorder, typically with childhood onset (although late-onset EA2 has been also reported [21]), characterized by paroxysmal attacks (lasting hours to days) of cerebellar dysfunction which are commonly triggered by emotional and physical stress. Some patients may exhibit mild interictal cerebellar ataxia or isolated nystagmus or, more rarely, severe progressive ataxia [11]. EA2 is caused by CACNA1A mutations that mostly result in truncation of the encoded CaV2.1 α1A channel subunit, while missense mutations have also been reported [22]. Although most of the missense mutations are located in the pore regions of the channel, there are at least five mutations of highly conserved residues found in the voltage sensor domains [11,23–25]. Usually, these mutations have negative effects
on both channel activity and trafficking to the plasma membrane when studied in heterologous expression systems [11,23–26]. At present it is unknown whether aberrant trafficking of CaV2.1 EA2 mutants also occurs in patients’ neurons. It has been reported that the spontaneous ataxic mouse model rolling Nagoya (carrying CaV2.1 R1262G mutation at S4-DIII) has reduced voltage sensitivity and activity of the CaV2.1 channel but shows unaltered expression in mouse cerebellar Purkinje cells in contrast to heterologously expressed R1262G channels showing strongly reduced expression and/or targeting to the plasma membrane [27]. Therefore, other channel function modifications beyond the decreased intracellular trafficking may lie beneath the pathophysiological role of CaV2.1 in EA2 patients. In this sense, it has been reported that several CaV2.1 EA2 mutations (affecting pore or voltage sensor regions) produce loss-of-channel-function by shifting channel activation to more depolarized voltages [25,26,28–31], thus reducing CaV2.1 open probability [31]. Besides, A454T mutation (located at the first intracellular loop connecting domains I and II of α1A) has been linked to a heterogeneous ataxic disorder with clinical features midway between EA2 and spinocerebellar ataxia type 6 (SCA6, other allelic disorder associated with mutations in the CACNA1A gene) [32]. Mutation A454T also produces loss-of-channel function by altering the functional interaction between α1A and SNARE proteins thus leading to a decreased channel coupling to exocytosis [2]. Regardless of the mechanism employed by CaV2.1 EA2 mutations, studies derived from an EA2 KI mouse model (carrying the loss-of-function pore mutation F1406C) suggest that motor deficit apparently results from subtle dysfunction of multiple cerebellar cell types [33].

SCA6 is a late-onset slowly progressive ataxic syndrome with underlying cerebellar atrophy. It is caused by small expansions of a polyglutamine (polyQ) sequence, encoded by CAG trinucleotide repeats, at the C-terminal end of some CaV2.1 splice variants [34]. Studies in SCA6 KI mice show that the polyQ expansions do not alter CaV2.1 biophysical properties and suggest that the markedly selective degeneration of cerebellar Purkinje cells (and the subsequent motor impairment) is due to the toxic accumulation of the expanded polyQ channel [11,35].

Several HM-linked CACNA1A gain-of-function mutations also produce permanent cerebellar symptoms ranging from slowly progressive cerebellar ataxia and/or nystagmus (with cerebellar atrophy in some cases) [14,36,37] or permanent ataxia [38,39] to early-onset cerebellar signs consistent with congenital ataxia [40–44]. In an attempt to understand how a CACNA1A HM mutation can also lead to such severe clinical phenotype, the deletion of a highly conserved phenylalanine located at the S6 pore region of α1A domain III (ΔF1502), found in a case of congenital ataxia and hemiplegic migraine, has recently been functionally characterized [44]. The study, performed in Xenopus oocytes as heterologous expression system, only revealed discrete alterations in CaV2.1 channel function of unclear pathophysiological relevance, since channel activity was measured with Ba2+ as the charge carrier and not with the physiological permeant ion Ca2+. The most relevant detected effect was an ~ 11 mV hyperpolarizing shift of the voltage-dependent channel activation, similar to the one reported for all HM mutations analyzed so far (including those that do not lead to cerebellar symptoms) [13,14] (for a review see [11]). Such gain-of-function effect fits well with a pathophysiological role of mutation ΔF1502 in HM but it seems not enough to explain its involvement in congenital ataxia per se [44]. Here, we analyze the functional consequences of the ΔF1502 α1A mutation (found in a second case of congenital ataxia) on CaV2.1 human channels heterologously expressed in mammalian tsA-201 HEK cells, using the physiological ion Ca2+ as the charge carrier. Our results reveal that ΔF1502 is a strong gain-of-function mutation, as it powerfully decreases the voltage threshold for channel activation (by ~ 21 mV). This effect, in combination with ΔF1502-induced changes in the kinetics of activation, deactivation and inactivation of CaV2.1 channels, allow significantly higher Ca2+ influx in response to stimuli of physiological traits, and support the
causative role of ΔF1502 (and, by extension, of other gain-of-function CaV2.1 mutations) in congenital ataxia and/or cerebellar atrophy.

Materials and Methods

Brain Magnetic Resonance Imaging (MRI) Protocol

MR data were acquired using a 1.5 T scanner (MAGNETOM Symphony or MAGNETOM Vision, Siemens, Erlangen, Germany) equipped with a circular polarized receiver head array coil. Sagittal, transverse and coronal conventional spin-echo T1-weighted sequences were obtained (repetition time [TR] /echo time [TE]/acquisitions 450–600 ms/12-20 ms/2). In addition, transverse T2-weighted fast spin-echo (TR 4300 ms/TE 96 ms/acquisitions 1–2) and fast-FLAIR (TR 8500 ms/TE 104 ms/inversion time 2500 ms/acquisitions1) were also performed. All sequences were obtained with 4-5-mm section thickness and .1-.3 interslice gap, 144–256 × 256–384 matrix, and 196 × 230 mm field of view.

Genetic Analyses

Sample preparation and sequencing. DNA from the trio (patient and parents) was extracted from blood following a standard salting-out protocol. An ultra sound device (Covaris, Woburn, MA, USA) was used for shearing of 1 μg of genomic DNA aiming for a fragment size of 300-400bp. Library generation was performed using the TruSeq DNA kit (Illumina, San Diego, CA, USA) following supplier’s instructions. Pools of six samples were subjected to whole exome capture applying Nimblegene SeqCap EZ Human Exome version 3 (Roche NimbleGen, Madison, WI, USA) followed by sequencing on a HiSeq 2500 using the 2x100bp protocol. We obtained a coverage of at least 30-fold in > 80% of the probes.

Alignment and variant detection. Sequencing data preparation, read alignment and variant prediction was performed according to the ‘GATK best practice’ recommendations for a small number of samples [45]. In brief, sequencing reads were aligned to the hg19 reference genome using BWA-MEM (version 0.7.7) [46], followed by GATK indel realignment and base quality recalibration. Variants were predicted using GATK UnifiedGenotyper (version 3.1.1) (SNVs) and ClinDel (Indels) [47] in regions covered by SeqCap probes extended by 150 nt.

Variant annotation and prioritization. Identified genetic variants were subjected to annotation using ANNOVAR [48]. In addition information on population allele frequencies (1000 genomes, Exome Variant Server, dbSNP), damage estimation (PolyPhen-2 [49], SIFT [50], Condel [51], CADD [52]), evolutionary conservation in mammals (phastCons [53]) and genomic structure (e.g. segmental duplications) was supplemented using an in-house database.

To identify potentially causal variants, annotated variants were subjected to filtering and prioritization using both functional annotations (e.g. population allele frequency, impact on protein function, conservation etc.) and pedigree information. We performed causal variant prioritization based on four possible modes of inheritance: recessive, compound heterozygous, X-linked and de novo. The reduced gene list was furthermore ranked using ENDEAVOUR [54], which has been trained on a list of known genes related to spinocerebellar ataxias (SCA) extracted from Online Mendelian Inheritance in Man (OMIM) [55] and the muscle gene table [56]. The list of training genes consisted of ABCB7, AFG3L2, ANO10, ATP2B3, ATXN1, ATXN2, ATXN3, ATXN7, ATXN8, ATXN10, ATXN8OS, BEAN1, C10orf2, CABC1, CACNA1A, EEF2, FGFR1, GRM1, ITPR1, KCNC3, KCND3, NOP56, PDYN, PNPLA6, POLG, PPP2R2B, PRKCG, SETX, SPTBN2, SYNE1, SYT14, TBP, TDP1, TGM6, TPP1, TTBK2, WWOX, ZNF592. The highest ranking variant in the affected child (de novo indel in CACNA1A) was selected for further validation and functional studies.
**Sanger Validation.** Direct sequencing was carried out to confirm the CACNA1A de novo indel identified through whole-exome sequencing (WES). To that end, CACNA1A exon 28 (containing the nucleotide triplet deleted) from the proband and progenitors, was amplified by PCR, purified and sequenced using the BigDye Terminator cycle sequencing kit v3.1 and an automated sequencer ABI PRISM 3730 DNA Analyzer (Applied Biosystems, Foster City, CA, USA) (primer sequences and PCR procedures are available from the authors upon request).

**Ethics Statement**

The present investigation was conducted according to the principles expressed in the Declaration of Helsinki and was approved by the Ethics Committee of the Institute for Research in Biomedicine (IRB) at Vall d’Hebron University Hospital. Written informed consent was obtained from the parents for participation in this study, including the genetic analyses in the trio (patient and his parents) and the pathological analyses in the patient.

**cDNA Constructs and Site-Directed Mutagenesis**

cDNA of the human voltage-gated Ca\(^{2+}\) (Ca\(_{V}\)2.1) channel \(\alpha_{1A}\) subunit (originally cloned into a pCMV vector) was a gift from Professor J. Striessnig (University of Innsbruck, Austria). cDNAs of the rabbit \(\alpha_{2}\delta\) and rat \(\beta_{3}\) regulatory subunits (subcloned into a pcDNA3 expression vector) were gifts from Dr. L. Birnbaumer (National Institutes of Health, North Carolina, USA). \(\text{Ca}_{V}2.1\ \Delta F1502\) mutant channel was generated by deleting the CTT codon corresponding to residue F1502 of the human \(\alpha_{1A}\) subunit using site-directed mutagenesis (GenScript Corporation, Piscataway, NJ).

All cDNA clones used in this study were sequenced in full to confirm their integrity.

**Heterologous Expression and Electrophysiology**

tsA-201 HEK cells were transfected using a linear polyethylenimine (PEI) derivative, the polycation ExGen500 (Fermentas Inc., Hanover, Maryland, USA) as previously reported (eight equivalents PEI/3.3 \(\mu\)g DNA/dish) [13]. Transfection was performed using the ratio for \(\alpha_{1A}\) (wild-type (WT) or \(\Delta F1502\)), \(\beta_{3}\), \(\alpha_{2}\delta\), and EGFP (transfection marker) cDNA constructs of 1:1:1:0.3. Recordings were done 24–48 h after transfection at room temperature (22–24°C).

\(\text{Ca}^{2+}\) currents (\(I_{\text{Ca}^{2+}}\)) through WT or \(\Delta F1502\) \(\text{Ca}_{V}2.1\) channels were measured using the whole-cell configuration of the patch-clamp technique as described in detail previously [13]. In brief, pipettes had a resistance of 2–3 M\(\Omega\) when filled with a solution containing (in mM): 140 CsCl, 1 EGTA, 4 Na\(_{2}\)ATP, 0.1 Na\(_{3}\)GTP, and 10 HEPES (pH 7.2–7.3 and 290–300 mOsmol/l). The external solution contained (in mM): 140 tetraethylammonium-Cl (TEACl), 3 CsCl, 2.5 CaCl\(_{2}\), 1.2 MgCl\(_{2}\), 10 HEPES and 10 D-glucose (pH 7.4 and 300–310 mOsmol/l). When measuring Ba\(^{2+}\) currents, CaCl\(_{2}\) was replaced with an equimolar concentration of BaCl\(_{2}\). Recordings were obtained with a D-6100 Darmstadt amplifier (List Medical, Germany) and the pClamp8 software (Axon Instruments, Foster City, CA, USA) was used for pulse generation, data acquisition and subsequent analysis.

Peak inward \(\text{Ca}^{2+}\) currents in response to 20 ms depolarizing pulses were measured from cells clamped at -80 mV, as described in detail previously [13]. In order to obtain the voltage-dependence of channel activation, single normalized current-voltage (I-V) relationships were fitted with the modified Boltzmann equation, as previously reported [13]:

\[
I = \frac{G_{\text{max}}(V - V_{\text{rev}})}{1 + e^{\left(\frac{V - V_{1/2}}{k_{\text{act}}}ight)}}
\]  

(1)
where $I$ is the peak current, $G_{\text{max}}$ is the maximal conductance of the cell, $V$ is the membrane potential, $V_{\text{rev}}$ is the extrapolated reversal potential of $I_{\text{Ca}^{2+}}$, $V_{1/2 \text{ act}}$ is the voltage for half-maximal current activation, and $k_{\text{act}}$ is the slope factor of the Boltzmann term.

Kinetics of activation, deactivation, inactivation and recovery from inactivation for WT and ΔF1502 CaV2.1 channels were estimated as described in detail previously [13], with slight modifications. In particular, time constants for deactivation ($\tau_{\text{deactivation}}$) were obtained from single exponential fits of tail currents obtained with 10 ms prepulse to +20 mV (for WT channels) or -5 mV (for ΔF1502 channels) (to maximally open CaV2.1 channels) and followed by test pulses between -80 and 0 mV (in 5 mV steps) for 30 ms; and time course of $I_{\text{Ca}^{2+}}$ recovery from inactivation was tested by applying a second pulse of 50 ms to +20 mV at increasing time intervals (1–206 s) after an inactivating 3 s prepulse, and relative current at different times (normalized by the peak Ca$^{2+}$ current obtained during the 3s prepulse) was fitted to a single exponential.

The voltage dependence of steady-state inactivation was estimated by measuring peak Ca$^{2+}$ currents in response to depolarizing pulses (to +20 mV for WT channels and to -5 mV for ΔF1502 channels) from a holding of -80 mV, following 30 s steps to various holding potentials (conditioning pulses) between -80 and +5 mV. As described in detail previously [13], half-maximal voltage ($V_{1/2 \text{ inact}}$) and slope factor ($k_{\text{inact}}$) for steady-state inactivation were obtained by fitting normalized $I_{\text{Ca}^{2+}}$ persistent currents to the following Boltzmann equation:

$$\frac{I}{I_{\text{max}}} = \frac{1}{1 + e^{\frac{V - V_{1/2 \text{ inact}}}{k_{\text{inact}}}}}$$

(2)

The quality of all fittings performed in the present work was always high, with adjusted R-squared values close to 1 (ranging between 0.95 and 0.99).

Ca$^{2+}$ entry through WT and ΔF1502 CaV2.1 channels was also measured in response to three different action potential-like waveforms (APWs) that have been reported to represent a wide range of action potential durations present in neurons [13,57]. In brief, the duration above half-amplitude and the rising phase slope were, respectively: 0.5 ms and 367 mV/ms for the fast APW, 1 ms and 114 mV/ms for the medium APW and 2.2 ms and 105 mV/ms for the slow APW. All APWs were normalized to a resting potential of -80 mV and peak amplitude of +30 mV. Ca$^{2+}$ currents were acquired at 33 kHz and corrected for leak and capacitive currents using the leak subtraction procedure (P/4). As described previously [13], total Ca$^{2+}$ influx ($Q_{\text{Ca}^{2+}}$) in response to APWs was calculated as the integral of the Ca$^{2+}$ current delimited by the time point at which inward current initially diverged from the baseline, and the time at which it returned to baseline. That time was considered as the time for Ca$^{2+}$ entry. Trains of 1000 fast and medium APWs (applied at the highest frequency allowed by the corresponding electrophysiological protocol including P/4 leak subtraction procedure: 50 Hz and 42 Hz, respectively) were applied in some experiments in order to measure Ca$^{2+}$ entry through WT and ΔF1502 CaV2.1 channels in response to repetitive, brief depolarization of physiological relevance in neurons. Accumulative Ca$^{2+}$ influx along the different trains of APWs was calculated by adding the $Q_{\text{Ca}^{2+}}$ values obtained for each single APW stimulus in the corresponding train.

Statistics

Data are presented as the means ± S.E.M. Statistical tests included unpaired or paired Student’s $t$ test or, Mann-Whitney U-test, as appropriate. Differences were considered significant if $P < 0.05$. 
Results

ΔF1502 CaV2.1 Mutant in a Spanish Case of Congenital Ataxia

This 7 year-old boy was normally born after an uneventful pregnancy to unrelated parents. He was noted to be hypotonic and lag behind in motor development over the first months of life. A younger 3 year-old brother is healthy. Examination at the age of 5 months, revealed an alert, non-dysmorphic infant, with good visual fixation but saccadization of pursuit gaze; there was global hypotonia without any evidence of muscle weakness or atrophy; deep tendon reflexes were preserved. Motor development was delayed from early on: he attained head control by age 6 months, sat unassisted at age 3 years. Currently remains in the upright position with aid of a stander and uses a wheel chair for ambulation.

At the age of 7 years the patient has developed a complete ataxic syndrome. He is able to understand simple commands and speaks in short sentences. He is quite sociable and attends a special school. He is able to draw or self-feed with spoon. On examination, he is normocephalic and there are no telangiectasias or organomegalies. There is a fine, conjugate horizontal/rotary nystagmus and a complex alteration of ocular pursuit that resembles oculomotor apraxia, prominent head and trunk titubation, diffuse hypotonia, normal strength, brisk deep-tendon reflexes, flexor plantar responses and mild upper limb dysmetria with no tremor. He can adopt a quadrupedal position but is not able to stand or walk holding onto furniture. Ancillary tests included serum creatine kinase, vitamin E, alpha fetoprotein, immunoglobulins, thyroid hormones, amino acids, transferrin isoelectric focusing, urine organic acids, CSF lactate, pterins, folate and dopamine and serotonin metabolites. A comparative genomic hybridization array showed a 225 Kb segmental monosomy in the sexual chromosomes pseudoautosomal region (PAR2). Although this rearrangement affected the dose of SPRY3 and VAMP7, it was also found in his asymptomatic father. Fibroblast beta-galactosidase, beta-D-glucuronidase, beta-glucosidase, beta-N-acetyl-glucosaminidase, hexosaminidase A, alpha-galactosidase and alpha-glucosidase activities were normal. A neurophysiological study showed normality of motor and sensory neurography, EMG and somatosensory evoked responses. Visual evoked potentials (flash) and electoretinogram were normal. A muscle biopsy disclosed normal histochemistry and normal activities of the respiratory chain enzymes. A brain magnetic resonance imaging (MRI) at the age of 14 months did not reveal alterations. Subsequent studies performed at the ages of 28 months and 4 years showed a conspicuous and progressive, predominantly vermian, cerebellar atrophy with no involvement of other brain areas (Fig 1).

Due to the large number of genes potentially causing cerebellar ataxia, we performed whole exome sequencing (WES) of a parent-child trio with an unknown cause of congenital ataxia in the child. Variant detection on the sequencing data using GATK [45] and ClinDel [47] yielded 115,818 and 12,753 variants, respectively. Variants affecting the protein sequence (nonsynonymous or splicing) were filtered based on possible inheritance modes, including de novo, recessive, compound heterozygous or X-linked. Variants coherent with one of the inheritance modes were further prioritized based on population allele frequency in EVS and 1000GP (i.e. rare variants with < 1% AF), damage potential based on PolyPhen-2, SIFT, Condel and CADD [49–52], evolutionary conservation based on phastCons [53] and finally sequence complexity and repetitiveness (e.g. variants in segmental duplications are removed), finally yielding a total of seven de novo, eight recessive and 15 compound heterozygous variants that are rare or novel and highly damaging. The affected 30 genes were subsequently subjected to additional prioritization using ENDEAVOUR [54], which has been trained on genes extracted from various disease gene resources [55,56]. The ENDEAVOUR prioritization highlighted a de novo triplet deletion in CACNA1A (NM_001127221.1-transcript variant 3:c.4503-4505delCTT) as most likely candidate, as being part of the list of training genes. Furthermore, no other genes after
filtering could be linked to the investigated phenotype. Manual review of the respective alignment data supports the presence of the deletion that was confirmed as a \textit{de novo} variant by Sanger sequencing (Fig 2). This heterozygous CACNA1A deletion brings about a $\Delta F1502$ change in the Cav2.1 $\alpha_{1A}$ channel subunit, previously described in association with both congenital ataxia and hemiplegic migraine \cite{44}.

**Fig 1.** Brain MRI of the proband at the age of 14 months (A), 28 months (B), and 4 and a half years (C,D). After the initial normal findings (A), note the progressive cerebellar atrophy mainly involving the complete vermis (indicated by the arrows in B, C). The hemispheres, displaying prominence of the cerebellar folia, were eventually affected (D).
ΔF1502 Alters Current Density and Activation, Deactivation and Inactivation Features of Human CaV2.1 Channels

The F1502 residue of the human CaV2.1 α1A channel subunit is the third amino acid containing a non-polar aromatic side chain of the three phenylalanine’s group (F1500, F1501, F1502), highly conserved in the pore-forming region of the channel. Thus, F1502 residue lies in all S6 segments of domains III (DIII-S6) of all members of the human CaV2 channel family (CaV2.1 or P/Q-type, CaV2.2 or N-type and CaV2.3 or R-type channels). Besides, F1502 is also conserved through evolution as shown by a comparison of orthologous CaV2.1 channels (Fig 3A). In human CaV1.x and bacterial voltage-gated Na+ (NaVAb) channels, a different non-polar but aliphatic side chain amino acid (methionine) occupy the equivalent F1502 residue position (Fig 3B). CaV2.1 F1502 is located eight residues upstream of a highly conserved isoleucine contributing to the ring of hydrophobic residues that seems to form the internal pore gate of voltage-gated ion channels [58]. F1502 homologous methionine residue in the NaVAb crystal structure is facing to the channel pore, without any evident interaction with other segments either in the pore or the voltage-sensing regions (Fig 3B, 3C and 3D).

Maximal Ca^{2+} current densities for expressed mutant ΔF1502 α1A in tsA-201 HEK cells were ~ 60% smaller than current densities for wild-type (WT) α1A channels (Fig 4A and 4C, left panel). The potential for half-maximal activation (V_{1/2 act}) was strongly left-shifted for ΔF1502 CaV2.1 channels by ~ 21 mV (P < 0.0001, Student’s t test), with a significant 0.9 mV increase (P < 0.001, Student’s t test) in the steepness of the activation curve (k_{act}) (Fig 4C, right panel; mean ± SEM values for V_{1/2 act} and k_{act} are provided in the figure legend). Accordingly, the maximal Ca^{2+} current amplitude was induced by depolarizing pulses to +15 mV or -5 mV for WT or ΔF1502 channels, respectively (Fig 4C). Due to this ΔF1502-induced left-shift in CaV2.1 channel activation, Ca^{2+} current densities through mutant channels were significantly higher than current densities through WT channels (P < 0.05–0.0001, Mann-Whitney U-test) in a range of depolarized voltages with physiological relevance in neurons (from -40 to -5 mV) (Fig 4C, left panel; S1 Table). Activation and deactivation kinetics were also considerably left-shifted in the ΔF1502 channel (Fig 4D and 4E, respectively): the highest τ_{activation} for WT

Fig 2. De novo heterozygous CACNA1A deletion in congenital ataxia with cerebellar atrophy. (A) Pedigree of the affected individual carrying the de novo heterozygous ΔF1502 mutation. White symbols denote healthy individuals and grey, congenital ataxia. (B) Electropherograms showing the deleted nucleotides (bracket) (NM_001127221.1-transcript variant 3:c.4503-4505delCTT) leading to a F1502 deletion (NM_001120693.1). Note the double wild-type (WT) and mutant (ΔF1502) sequence in the patient’s electropherogram (heterozygous mutation carrier).

doi:10.1371/journal.pone.0146035.g002
Fig 3. Evolutionary conservation of the F1502 residue and predicted location at the channel pore. (A) Sequence alignment of individual S6 segments at domains I to IV (D-I-DIV) of human CaV2.1 channel α₁ subunits (P/Q type CaV2.1; N-type CaV2.2; R-type CaV2.3), human CaV1.x channel α₁ subunits, and the bacterial sodium channel NaVAb (top); sequence alignment of S6-DIII of CaV2.1 channels from different species (as indicated). The three Phenylalanine group (in red) is conserved in the human CaV2.1 channel α₁A subunit, where F1502 is located at the third position. This particular amino acid residue is only conserved
(2.5 ± 0.2 ms, n = 27) or ΔF1502 (3.4 ± 0.3 ms, n = 19) Ca²⁺ currents were observed at +5 mV and -20 mV, respectively. In addition, activation kinetics of ΔF1502 channels were significantly accelerated (P < 0.05 – 0.0001, Mann-Whitney U-test) in a wide range of depolarizing voltages (from 0 to +55 mV), when compared to WT channels (Fig 4A and 4D; S2 Table). Concerning gate closing, ΔF1502 CaV2.1 channels presented slower τ deactivation at voltages from -80 to -20 mV (Fig 4B and 4E; S3 Table, P < 0.0001, Mann-Whitney U-test).

Next, we studied whether ΔF1502 affects the time course of channel inactivation by analyzing the Ca²⁺ current decay during a 3-s test pulse elicited from a holding potential of -80 mV to +20 mV (Fig 5A). We found that inactivation kinetic for ΔF1502 Ca²⁺ currents was significantly slower (τ inactivation = 397.3 ± 37.1 ms, n = 8) than for WT currents (τ inactivation = 121.3 ± 17.4 ms, n = 10) (Fig 5B, P < 0.0001, Student’s t test). However, the rate of recovery from inactivation was unaffected in ΔF1502 channels (Fig 5C, P = 0.5, Student’s t test). The half-maximal voltage for steady-state inactivation (V1/2 inact) induced by 30s conditioning prepulses between -80 and +5 mV was greatly left-shifted (~ 28.5 mV) in ΔF1502 channels (P < 0.0001, Student’s t test), without significant change in the steepness of the inactivation curve (symbolized by k inact) (P = 0.89, Mann-Whitney test) (Fig 5D and 5E).

Effect of ΔF1502 over CaV2.1 Mediated Ca²⁺ Influx Evoked Either by Single or Trains of Action Potential-Like Waveforms

To better understand the physiological impact of ΔF1502 effects on CaV2.1 channel activity, we measured the Ca²⁺ influx through WT and mutant channels elicited by single action potential-like waveforms (APWs) of different durations (fast, medium and slow; Fig 6A, top; for further details see Materials and Methods [13,57]). In spite of the significant reduction in maximal Ca²⁺ current density produced by ΔF1502 (in this set of experiments maximal Ca²⁺ current density through ΔF1502 channels in response to a 20 ms depolarizing pulse was ~ 50% smaller when compared to WT current, S1 Fig, left panel), no significant changes among cells expressing either WT or ΔF1502 channels were observed regarding the peak Ca²⁺ current density elicited by the different APWs (Fig 6A and 6B, top panel). Besides, and more important, total Ca²⁺ influx (QCa²⁺) in response to APWs was not reduced by ΔF1502. Not only that, but the amount of Ca²⁺ that entered into the cell in response to fast and medium APWs was significantly higher for cells expressing the CaV2.1 mutant channel (Fig 6A and 6B, second panel), most probably due to the ~ 18.7 mV ΔF1502-induced left-shift in the activation curve observed in this set of cells (S1 Fig, right panel). This, in combination with the effects that ΔF1502 exerts on channel activation and deactivation kinetics, may also explain another two facts: the time required to reach the peak current density in response to all APWs was always significantly higher in cells expressing the mutant CaV2.1 channel (Fig 6A and 6B, third panel); and the time of Ca²⁺ entry in response to fast and medium APWs was significantly higher in cells expressing the mutant CaV2.1 channel (Fig 6A and 6B, bottom panel).
Fig 4. ΔF1502 induces a gain-of-function in the heterologously expressed Ca\textsubscript{v}2.1 channel by affecting its activation and deactivation properties. (A) Representative current traces elicited by 20 ms depolarizing pulses from -80 mV to the indicated voltages (inset), illustrating the difference in voltage-dependence and activation kinetics between wild-type (WT) (left) and ΔF1502 (right) Ca\textsubscript{v}2.1 channels. Dotted lines indicate the zero current level. (B) Representative current traces showing distinct deactivation kinetics of WT (left) and ΔF1502 (right) Ca\textsubscript{v}2.1 channels, obtained by hyperpolarizing the cells during 30 ms at the indicated voltages (inset) following a 20 ms depolarizing pulse to +20 mV (for WT channels) or -5 mV (for ΔF1502 channels).
As ΔF1502 strongly promotes CaV2.1 channel steady-state inactivation by voltage in response to prolonged depolarization (Fig 5D and 5E), we also evaluated if this last action is relevant for Ca\(^{2+}\) influx through the channel under physiological conditions. In vivo, neurons do not experience long depolarization to induce CaV2.1 steady-state inactivation. Instead, this effect on CaV2.1 channel activity is mimicked by the occurrence of more physiological stimuli, such as trains of action potentials causing repetitive, brief depolarization [59]. Therefore, given that total Ca\(^{2+}\) influx (Q\(_{Ca}^{2+}\)) in response to single fast and medium APWs was favored by ΔF1502, we studied the effect of the mutation on Q\(_{Ca}^{2+}\) elicited by trains of fast and medium APWs applied at relatively high frequency in two new sets of experiments, where it can be observed again the reduction in maximal Ca\(^{2+}\) current density (by ~50%) and the shift of the current activation curve to lower voltages (~20 mV) induced by ΔF1502 (Figs 7A and 8A). The application of a train of fast APWs (1 ms duration, with maximal depolarization to +30 mV from a holding potential of -80 mV, applied at 50 Hz for 20 seconds) did not cause a significant reduction in Ca\(^{2+}\) influx through WT CaV2.1 channels (Q\(_{Ca}^{2+}\) produced by the first APW applied was 1.94 ± 0.3 fC/pF (n = 9) and at the end of the train the observed Q\(_{Ca}^{2+}\) value was 1.76 ± 0.3 fC/pF (n = 9), P = 0.23, paired Student’s t test). However, and according to the effect of ΔF1502 on CaV2.1 channel steady-state inactivation, the same train of fast APWs produced a small, but significant, reduction (by ~19%) in Ca\(^{2+}\) influx through ΔF1502 CaV2.1 channels (from 5.76 ± 0.7 fC/pF to 4.69 ± 0.6 fC/pF (n = 7), P < 0.01, paired Student’s t test) (Fig 7B and 7C). Nevertheless, in spite of this Ca\(^{2+}\) entry reduction along the train produced by ΔF1502, Q\(_{Ca}^{2+}\) after each APW stimulus was always higher for mutant channels (Fig 7B and 7C) and, therefore, accumulative Ca\(^{2+}\) influx through ΔF1502 CaV2.1 channels was still significantly higher than through WT channels (4.7 ± 0.4 pC/pF (n = 7) versus 1.9 ± 0.3 pC/pF (n = 9), P < 0.0001, Student’s t test). Similar conclusions can be drawn from the analysis of studies using trains of medium APWs (2 ms duration, with maximal depolarization to +30 mV from a holding potential of -80 mV, applied at 42 Hz for 23.81 seconds) (Fig 8). In this case, the train of APWs produced a significant reduction in Ca\(^{2+}\) influx through both, WT (from 9.27 ± 2.14 fC/pF to 6.97 ± 1.57 fC/pF (n = 10), P < 0.01, paired Student’s t test) and ΔF1502 (from 20.81 ± 1.9 fC/pF to 9.6 ± 1.3 fC/pF (n = 11), P < 0.0001, paired Student’s t test) CaV2.1 channels, which was significantly greater for mutant channels (54.65 ± 4.4% (n = 10) versus 23.69 ± 2.9% (n = 11), P < 0.0001, Student’s t test) (Fig 8B and 8C). Yet, accumulative Ca\(^{2+}\) influx through ΔF1502 CaV2.1 channels all along the train was significantly higher than through WT channels (13.4 ± 1.4 pC/pF (n = 11) versus 7.9 ± 1.8 pC/pF (n = 10), P < 0.05, Student’s t test) (Fig 8B and 8C).

**Discussion**

Genetic variants in the gene encoding the pore-forming CaV2.1 (P/Q-type) channel α\(_{1A}\) subunit (CACNA1A) result in heterogeneous human neurological disorders of autosomal dominant inheritance, including familial and sporadic hemiplegic migraine (FHM/SHM), episodic ataxia type 2 (EA2), and spinocerebellar ataxia type 6 (SCA6). Although hemiplegic migraine (HM) is linked to CACNA1A mutations that enhance CaV2.1 channel activity and EA2, on the
Fig 5. ΔF1502 affects CaV2.1 channel inactivation properties. (A) Representative current traces illustrating the slower inactivation kinetics for ΔF1502 CaV2.1 channels (red trace) when compared to WT channels (blue trace), in response to a 3 s depolarizing pulse to +20 mV. (B) Average τ inactivation values of Ca2+ currents through WT (open bar, n = 10) and ΔF1502 (filled bar, n = 8) CaV2.1 channels, elicited as indicated in panel (A). (C) Similar time course of Ca2+ current recovery from inactivation for WT and ΔF1502 CaV2.1 channels. Average τ of current recovery from inactivation obtained after fitting the data to a single exponential (solid color lines), were (in s): WT (open circles, n = 7) 15.5 ± 1.1; ΔF1502 (filled circles, n = 5) 16.9 ± 2.1 (P = 0.5, Student’s t test). (D, E) Steady-state inactivation of WT and ΔF1502 CaV2.1 channels. Amplitudes of currents elicited by test pulses to +20 mV (for WT channels) or -5 mV (for ΔF1502 channels) were normalized to the current obtained after a 30 s prepulse to -80 mV and fitted by a single Boltzmann function (solid color traces) (see Materials and Methods, Eq 2). Average V1/2 inact and k_inact values were (in mV): WT (open circles, n = 19) -32.2 ± 2.1 and -5.3 ± 0.3; ΔF1502 (filled circles, n = 12) -60.7 ± 1 and -5.2 ± 0.8, respectively. No significant difference was found for k_inact values (P = 0.89, Mann-Whitney test).
Fig 6. ΔF1502 effects on Ca\textsuperscript{2+} influx evoked by single action potential-like waveforms (APWs). (A) Average Ca\textsuperscript{2+} current traces evoked by APWs of different durations (fast (left panels), medium (central panels) and slow (right panels) (see Materials and Methods for details) obtained from tsA-201 HEK cells expressing WT (blue traces) or ΔF1502 (red traces) Ca\textsubscript{v}2.1 channels. Dotted lines stand for the zero current level. (B) Average data for peak Ca\textsuperscript{2+} (I\textsubscript{Ca\textsuperscript{2+}}) current density (top panel), normalized Ca\textsuperscript{2+} influx (Q\textsubscript{Ca\textsuperscript{2+}}) (second panel), time to peak (third panel), and time for Ca\textsuperscript{2+} entry (bottom panel) in response to APWs of different durations obtained from cells expressing WT (blue bars, n = 12–14) or ΔF1502 (red bars, n = 8) Ca\textsubscript{v}2.1 channels (*P < 0.05, **P < 0.001 and ***P < 0.0001 when compared to WT).
Fig 7. ΔF1502 effects on Ca²⁺ influx evoked by a 50 Hz train of 1 ms action potential-like waveforms (APWs). (A) Average current density-voltage relationships (left) and normalized I-V curves (right) for WT (open circles, n = 9) and ΔF1502 (filled circles, n = 7) CaV2.1 channels expressed in tsA-201 HEK cells, before stimulation with a 50 Hz train of 1 ms APWs. In this series of experiments, maximal Ca²⁺ current density through CaV2.1 channels is still significantly reduced by ΔF1502 (left panel: from -100.92 ± 12.5 pA/pF (for WT, n = 9) to -47.18 ± 6.9 pA/pF (for ΔF1502, n = 7), P < 0.01, Student’s t test) and the significant left-shift induced by ΔF1502 on the CaV2.1 voltage-dependent activation is also present (right panel: WT V½ act
contrary, is associated to loss-of-function mutations, symptomatology overlap of HM, EA2 and SCA6 are well recognized at the clinical level (reviewed in [11]). As yet, it is not clear why some CACNA1A mutations cause pure FHM and other FHM with cerebellar signs. Functional studies in vitro show different effects on CaV2.1 steady-state inactivation, which can be increased, decreased, or unaltered depending on the mutation [11]. Besides, although all studied mutations share a consistent gain-of-function effect on CaV2.1 channel activation, there are no noticeable differences among these two groups of FHM mutations, with the exception of mutations D715E, S218L [11,18,60–62] and now ΔF1502 (this report). Hence, pure human FHM mutations such as R192Q and Y1245C (within voltage sensor domains of CaV2.1 α1A subunit) or V714A (affecting the pore S6 segment of α1A domain II) (S2 Fig) shift CaV2.1 channel activation to hyperpolarizing voltages by ~ 9 mV [13,16,17,63]. Likewise, human FHM mutations T501M and R583Q (located at voltage sensor domains, S2 Fig), which are linked to progressive cerebellar ataxia (with cerebellar atrophy in the case of R583Q) [14], decrease voltage-threshold for channel activation by ~ 7–10 mV [14,60]. The same applies to human FHM mutations T666M, I1811L (within pore domains) and R1350Q (also referred as R1349Q and homologous to the mouse R1252Q allele of the tottering, Cacna1atg, mutant series; located at the voltage sensor S4 segment of α1A domain III) (S2 Fig), which are linked to congenital ataxia [38–43] and shift CaV2.1 channel activation to lower voltages by ~ 6–12 mV [63,64]. However, mutation D715E (located at the pore S6 segment of α1A domain II, S2 Fig) induces a bigger decrease in the voltage-threshold for CaV2.1 channel activation (by ~ 17 mV) [60]. Likewise, the genetic variant S218L (at the loop between S4 and S5 segments of α1A domain I, S2 Fig) displays one of the largest gains of function on channel activation when compared with other FHM mutations, promoting Ca2+ influx even at small depolarization, which are insufficient to open wild-type (WT) channels. Such effect can be further potentiated by the slower inactivation kinetics and increased rate of recovery from inactivation reported for the S218L CaV2.1 channel [18,62]. These distinctive effects of mutations D715E and S218L may be enough to explain the severity of the cerebellar symptoms accompanying FHM in the carrier patients, and in particular the more severe clinical phenotype associated to S218L that, in addition to HM attacks and slowly progressive cerebellar ataxia and atrophy, also includes epileptic seizures, coma or profound stupor, and, sometimes fatal, cerebral edema [36,37,39]. Recently, Garcia-Segarra et al. have reported the deletion of the highly conserved phenylalanine 1502 (ΔF1502, located at the S6 pore region of α1A domain III), in association to a case of HM and congenital ataxia [44]. Their study about the functional consequences of ΔF1502 on CaV2.1 channel function in Xenopus oocytes using Ba2+ as the charge carrier (instead of the physiological permeant ion Ca2+), revealed: 1) an ~ 11 mV hyperpolarizing shift in CaV2.1 voltage-dependent activation, 2) a 30% decrease in Ba2+ current density at high depolarizing voltages, 3) a shift in the voltage dependence of steady-state inactivation to hyperpolarizing voltages by ~ 14 mV, and 4) a slightly slower recovery from channel inactivation. Although the gain-of-function effect on channel activation fits well with a pathophysiological role of mutation ΔF1502 in HM,
Fig 8. ΔF1502 effects on Ca$^{2+}$ influx evoked by a 42 Hz train of 2 ms action potential-like waveforms (APWs). (A) Average current density-voltage relationships (left) and normalized I-V curves (right) for WT (open circles, n = 10) and ΔF1502 (filled circles, n = 11) CaV2.1 channels expressed in tsA-201 HEK cells, before stimulation with a 42 Hz train of 2 ms APWs. In this series of experiments, maximal Ca$^{2+}$ current density through CaV2.1 channels is still significantly reduced by ΔF1502 (left panel: from -94.26 ± 18.9 pA/pF (for WT, n = 10) to -47.76 ± 5.7 pA/pF (for ΔF1502, n = 11), P < 0.05, Student's t test) and the significant left-shift induced by ΔF1502 on the CaV2.1 voltage-dependent activation is also noticed (right panel: WT V$_{1/2\ act}$= 2.32 ± 1.18 mV (n = 10) versus ΔF1502 V$_{1/2\ act}$ = -17.74 ± 0.35 mV (n = 11), P < 0.0001, Student’s t test). (B)
the relevance of these discrete alterations in CaV2.1 channel activity in the context of congenital ataxia remained unclear [44].

Here, we report a second case of congenital ataxia, in a 7-year-old boy, linked to the ΔF1502 α1A mutation, detected by whole-exome sequencing of a parent-child trio. Contrary to the previous reported case (a 13-year-old girl), our patient did not show HM symptoms, although this might be due to its lower age and, therefore, we cannot rule out the possibility that symptoms of HM appear in the future. Besides, our functional study using the physiological permeant ion Ca2+ provides robust evidences to consider the ΔF1502 α1A mutation per se responsible of such a severe cerebellar phenotype. Thus, ΔF1502 affects several biophysical properties of Ca2+-conducting CaV2.1 channels heterologously expressed in mammalian tsA-201 HEK cells: 1) strongly shifts the current activation curve towards hyperpolarized potentials (by ~ 21 mV), allowing significantly higher Ca2+ current densities in a range of depolarized voltages with physiological relevance in neurons, even though the mutation reduces maximal Ca2+ current density by 50–60%; 2) accelerates activation kinetics and slows deactivation kinetics of CaV2.1 within a wide range of voltage depolarization; 3) slows inactivation kinetic; and 4) shifts voltage-dependent steady-state inactivation to lower voltages (by ~ 28 mV). Despite a favored inactivation by voltage found in the mutant channel, ΔF1502 final effect on CaV2.1 results in a huge Ca2+ influx increase in response to stimuli of physiological relevance in neurons, such as either single or trains of action potential-like waveforms (APWs) of different durations. Studies from the homozygous knock-in (KI) mouse carrying the human FHM CaV2.1 R192Q mutation (which decreases voltage threshold of channel activation by ~ 10 mV) reveal that such gain-of-function mutation results in prolonged action potentials in some types of neurons [65]. Our data clearly show that Ca2+ influx (QCa2+), through both WT and ΔF1502 CaV2.1 channels, increases with the duration of the action potential-like waveforms (Figs 6, 7C and 8C; S3B and S3C Fig). Therefore, in those neuronal cells where CaV2.1 channels contribute to the shape of action potentials, the ΔF1502-induced increase in Ca2+ entry in response to physiological stimuli would be even greater than the one found in our comparisons, stimulating with single or trains of APWs of similar durations both WT and ΔF1502 CaV2.1 channels. Besides, the enhanced Ca2+ influx might even be further underestimated (see S3 and S4 Figs) if the observed reduction on maximal Ca2+ current density (by 50–60%) is due to aberrant trafficking of the mutant ΔF1502 CaV2.1 channel to the plasma membrane just occurring after heterologous expression in mammalian cells but not in patients’ neurons. Supporting this idea, the previous ΔF1502 functional study only reported a ~ 30% decrease in Ba2+ currents through mutant channels expressed in Xenopus oocytes [44], whereas we have observed a higher ~ 50–60% decrease in either Ca2+ (Figs 4C, 7A and 8A, S1 Fig) or Ba2+ (S5 Fig) currents through CaV2.1 ΔF1502 channels expressed in tsA-201 HEK cells. Indeed, a decreased density of functional CaV2.1 channels in the membrane (and a consequent decreased maximal whole-cell Ca2+ current density) depending on the cell expression system has been found for most FHM mutants compared to WT [11], making difficult to assess both the consequences of this effect in vivo and its real contribution to the associated clinical phenotypes, if any. Still, we cannot rule out
the possibility that altered pore gating and/or reduced channel conductance, rather than trafficking problems, are underneath the lower maximal current density through ΔF1502 CaV2.1 channels.

At the structural level, the affected F1502 residue is highly conserved in evolution at the interspecies level as well as among the S6 segments of domains III in the human CaV2 channel family (Fig 3A), indicating functional and/or structural relevance. Based on the crystal structure of the K+ channel KcsA, García-Segarra et al. proposed that F1502 is located in the distal half of S6 α helix that faces the cytosolic side, lining the inner pore vestibule of the channel [44]. We have used a different crystal structural model, the bacterial voltage-gated sodium channel (NaVAb), which shares 30% higher homology with human CaV2.1 (T-Coffee ~ 70% score) than the KcsA structural model (T-Coffee ~ 40% score), and found a similar predicted position in the inner pore vestibule for the F1502 residue. Accordingly, CaV2.1 F1502 is located eight residues upstream of a highly conserved isoleucine contributing to the ring of hydrophobic residues which has been suggested to form the internal pore gate in the voltage-gated ion channel superfamily [58]. Our results, along with those obtained from the functional characterization of other CaV2.1 mutations linked to FHM (with or without severe cerebellar symptoms) and located at the distal part of α1A S6 α helices (i.e. V714A, D715E and I1881L, see S2 Fig) [60,63], entail a relevant role of the internal pore mouth in the control of CaV2.1 voltage-dependent gating, affecting both activation and inactivation of the channel. Further studies are required to understand the precise molecular mechanisms by which this pore region influences the operation of voltage sensors in the CaV2.1 channel.

Purkinje cells (PCs) are the sole output from the cerebellar cortex that controls coordination of movement, maintenance of balance and motor learning after integration of multiple sensory and cortical synaptic inputs. Accordingly, defects in PCs firing is thought to be underneath cerebellar dysfunction and ataxia [11]. In this sense, the link between enhanced CaV2.1-mediated Ca2+ influx (as described here for the ΔF1502 mutant channel) and permanent or congenital ataxia can be inferred from studies of the homozygous KI mouse carrying the human pathogenic FHM CACNA1A S218L mutation (Cacna1aS218L/S218L), which exhibits the main features of the severe clinical syndrome linked to this mutation, including mild permanent cerebellar ataxia [66]. Certainly, it has been shown that the gain-of-function S218L mutation decreases the voltage threshold (by ~ 15 mV) for activation of CaV2.1 channels located in the soma and dendrites of mouse PCs, favoring the generation of somatic action potentials and dendritic Ca2+ spikes, and leading to irregular activity patterns. Interestingly, the action potential amplitude, half-width, maximum rising slope, maximum repolarizing slope, decay time constant as well as the basic membrane properties in Purkinje neurons from S218L KI mice were similar to WT cells. Altogether, these results suggest that CaV2.1 gain-of-function mutations affect the initiation threshold of action potentials, but they do not substantially modulate the characteristics of action potentials in murine cerebellar Purkinje neurons [6]. Besides, PCs hyperexcitability in S218L KI mice is further favored by increased Ca2+ influx through mutant S218L CaV2.1 channels located at the axon terminals and the subsequent enhancement of neurotransmitter release from excitatory afferent neurons including cerebellar granule cells and neurons in the inferior olive [6]. Independent of whether or not gain-of-function mutations alter the duration of action potentials and/or the firing properties of these afferent neurons (which is unknown at present), the enhanced release of neurotransmitters from their presynaptic terminals is consistent with our observation that single or trains of APWs promote Ca2+ entry through gain-of-function mutant CaV2.1 channels. Furthermore, both irregular PCs spiking and ataxic motor performance can be counteracted by activators of hyperpolarizing small-conductance Ca2+-activated K+ channels (SK channels), suggesting that the S218L-induced hyperexcitability of PCs is indeed the cause of the ataxic phenotype in the mouse model [6]. Similar or even larger
effects on cerebellar circuitry function may be produced by other CaV2.1 gain-of-function mutations (as ΔF1502) in humans. Functional alteration of cerebellum circuits by ΔF1502 can explain the fact that our patient presented neurological signs soon after birth and well before neuroimaging was able to disclose the slightest degree of cerebellar atrophy, whose subsequent development may be due to excitotoxic Ca²⁺ signaling causing PCs degeneration, as proposed for spinocerebellar ataxias [67].

Disruption of Ca²⁺ homeostasis leading to higher intracellular Ca²⁺ levels in cerebellar PCs and in synaptic terminals of granule cells has been related with functional and/or developmental defects in the cerebellum, leading to congenital ataxia forms in humans and similar ataxic phenotypes in animal models. Thus, two human missense mutations (S100P and G162R) in the CA8 gene, encoding carbonic anhydrase 8 (CA8), are linked to mild-to-severe forms of congenital ataxia [68,69]. CA8 is predominantly present in cerebellar PCs, where it interacts with the inositol 1,4,5-trisphosphate receptor type 1 (IP₃R1). This interaction impairs IP₃ binding [70,71], therefore modulating the ability of IP₃R1 to rapidly release Ca²⁺ from the endoplasmatic reticulum (ER). Mutation S100P induces proteasome-mediated degradation with a severe reduction of the level of CA8 protein [68], which is expected to promote ER-mediated intracellular Ca²⁺ signals that in turn may alter PCs synaptic inputs [72,73]. This mutation probably represents a null mutation similar to the 19 bp deletion in the Ca8 gene of the waddles mouse (a spontaneous animal model with ataxia), in which the lack of detectable Ca8 protein in the cerebellum results in abnormalities in cerebellar synaptic morphology and function [74,75]. More recently, a pivotal role for CA8 during embryonic development has been revealed by the knockdown of CA8 in zebrafish larvae, which results in increased neuronal cell death in the cerebellum and defects in motor and coordination functions, mimicking the CA8-associated ataxic phenotype found in humans and mice [76]. Although no studies are available regarding the effect of mutation G162R on either the function or expression of CA8, a deleterious effect supporting its pathogenicity has been suggested by bioinformatics analysis [69]. A missense mutation (G1107D) in the isoform 3 of the calmodulin-activated plasma membrane Ca²⁺ ATPases (PMCA3s) has been also associated to congenital cerebellar ataxia. Functional studies in a heterologous expression system show that mutated pump has reduced ability to extrude Ca²⁺ from the cell. As PMCA3 is highly expressed in the cerebellum, particularly in the excitatory presynaptic terminals of granule cells that make synapsis on PCs, the mutation might lead to higher basal levels of Ca²⁺ and/or altered local Ca²⁺ signaling that affect synaptic efficiency and promote PCs hyperexcitability [77].

In summary, our results highlight the key role of CaV2.1 channel gain-of-function not only in FHM but also in congenital ataxia, making this channel a strong potential drug target for direct, efficient and tailored disease treatment. Indeed, there are pharmacological evidences suggesting that inhibition of channel activity can provide a new therapeutic approach for the treatment of these neurological disorders. Thus, 2,5-di(tertbutyl)-1,4-benzoquinone (BHQ), a synthetic phenolic compound that inhibits sarcoendoplasmic Ca²⁺ ATPases (SER-CAs) and with pro-oxidant properties, can also inhibit CaV2.1 voltage-dependent activation to ameliorate gating defects in the channel and subsequently prevent synaptic transmission problems produced by the S218L CACNA1A mutation causing a severe form of FHM with slowly progressive cerebellar ataxia and atrophy in humans [78]. Nevertheless, due to the lack of selectivity on CaV2.1 channels, BHQ itself will not be therapeutically suitable, although modification of its chemical structure may yield small-molecule state-dependent selective inhibitors that could correct the mutation-induced gain-of-function in CaV2.1 activation. Such compounds would greatly improve the chances of developing a personalized medicine approach for CACNA1A-linked diseased states of the nervous system. So far, true CaV2.1 selective inhibitors are derived agatoxin family peptides. These peptides are not suitable therapeutic tools.
their mode of inhibition can give rise to undesirable side effects and have limited utility for in vivo studies.

Supporting Information

S1 Fig. I-V curves corresponding to seals included in the study of ΔF1502 effect on Ca\(^{2+}\) influx evoked by single action potential-like waveforms. Average current density-voltage relationships (left) and normalized I-V curves (right) for WT (open circles, n = 14) and ΔF1502 (filled circles, n = 8) Ca\(_V\)2.1 channels expressed in tsA-201 HEK cells. In this series of experiments, maximal Ca\(^{2+}\) current density through Ca\(_V\)2.1 channels is still significantly reduced by ΔF1502 (left panel: from -127 ± 23.4 pA/pF (for WT, n = 14) to -63.5 ± 15.3 pA/pF (for ΔF1502, n = 8), P < 0.05, Student’s t test) and the significant left-shift induced by ΔF1502 on the Ca\(_V\)2.1 voltage-dependent activation is also observed (right panel: WT V\(_{1/2\text{ act}}\) = 1.47 ± 0.6 mV (n = 14) versus ΔF1502 V\(_{1/2\text{ act}}\) = -17.2 ± 1.2 mV (n = 8), P < 0.0001, Student’s t test).

(TIF)

S2 Fig. Ca\(_V\)2.1 missense mutations causing early cerebellar dysfunction compatible with congenital cerebellar ataxia. (A) Location of human missense mutations associated to congenital ataxia and linked (purple circles) or not (purple triangles) to Familial Hemiplegic Migraine (FHM) in the secondary structure of the Ca\(_V\)2.1 α\(_{1A}\) channel subunit. For comparison, the location of some pure FHM-linked mutations (red circles) and FHM mutations including progressive ataxia (with cerebellar atrophy in some cases) (cyan circles) are also shown (for details of the corresponding references see S1 Text). The functional consequences of mutations shown in green have been characterized either by heterologous expression of recombinant Ca\(_V\)2.1 channels or by electrophysiological studies of native mutant Ca\(_V\)2.1 channels in neurons from knock-in mice. Note that mutation R1350Q has been also referred as R1349Q and is homologous to the mouse R1252Q allele of the tottering, Cacna1atg\(^{6}\), mutant series. (B) Sequences of S4 segments at domains I to IV (DI-DIV) of our Ca\(_V\)2.1 α\(_{1A}\) channel subunit clone, showing the affected R0 to R5 charged residues (or a neighboring residue) by mutations depicted in (A) (with a similar color pattern to indicate the clinical phenotype linked to the mutation). Positively charged residues in R0 to R5 positions, involved in the movement of the S4 segment in response to voltage, are delineated with a shaded background (gray). Note that R1349Q has been also referred as R1350Q and is equivalent to R1663Q in our α\(_{1A}\) clone. (C) Sequences of S6 segments at DI-DIV of our Ca\(_V\)2.1 α\(_{1A}\) channel subunit clone, showing the affected residues by mutations illustrated in (A) (with a similar color pattern to indicate the clinical phenotype associated to the mutation). Note that S1799L and I1811L correspond to S1801L and I1812L in our α\(_{1A}\) clone, respectively.

(TIF)

S3 Fig. Example of expected ΔF1502 effects on Ca\(^{2+}\) influx evoked by single action potential-like waveforms (APWs) in the case of unaffected current density. (A) Current density-voltage relationships (left) and the corresponding normalized I-V curves (right) for two particular tsA-201 HEK cells expressing either WT (open circles) or ΔF1502 (filled circles) Ca\(_V\)2.1 channels (maximal Ca\(^{2+}\) current density through WT and ΔF1502 Ca\(_V\)2.1 channels are -87.2 pA/pF and -80.8 pA/pF, respectively; V\(_{1/2\text{ act}}\) values for WT and ΔF1502 Ca\(_V\)2.1 channels are 2.95 mV and -15.17 mV, respectively). (B) Ca\(^{2+}\) current traces evoked by APWs of different durations (fast (left panels), medium (central panels) and slow (right panels) (see Materials and Methods for details) obtained from the two tsA-201 HEK cells indicated in panel A (showing similar maximal current densities) expressing either WT (blue traces) or ΔF1502 (red traces).
S4 Fig. Example of expected ΔF1502 effects on Ca2+ influx evoked by a 42 Hz train of 2 ms action potential-like waveforms (APWs) in the case of unaffected current density. (A) Current density-voltage relationships (left) and the corresponding normalized I-V curves (right) for two particular tsA-201 HEK cells expressing either WT (open circles) or ΔF1502 (filled circles) CaV2.1 channels (maximal Ca2+ current density through WT and ΔF1502 CaV2.1 channels are -87.8 pA/pF and -79.51 pA/pF, respectively; V1/2 act values for WT and ΔF1502 CaV2.1 channels are 1.56 mV and -15.87 mV, respectively). (B) Ca2+ current traces evoked by every 200th pulse of a 42 Hz train of medium (2 ms) APWs (see Materials and Methods for details) obtained from the two tsA-201 HEK cells indicated in panel A (showing similar maximal current densities) expressing either WT (left) or ΔF1502 (right) CaV2.1 channels. Dotted lines indicate the zero current level. (C) Values for Ca2+ influx normalized by cell size (QCa2+) in response to every 5th pulse of a 42 Hz train of medium (2 ms) APWs, obtained from these two cells expressing either WT (blue symbols) or ΔF1502 (red symbols) CaV2.1 channels.

(TIF)

S5 Fig. Effect of ΔF1502 on CaV2.1-mediated Ba2+ currents: reduction in IBa2+ density and ~11 mV left-shift in the voltage dependence of activation. Average current density-voltage relationships normalized by the absolute maximal value (left) and I-V curves normalized by the peak current obtained in each recording (right), for WT (open circles, n = 14) and ΔF1502 (filled circles, n = 9) CaV2.1 channels expressed in tsA-201 HEK cells using 2.5 mM BaCl2 instead of CaCl2 in the extracellular recording solution. ΔF1502 induces a ~61% significant reduction of maximal Ba2+ currents through CaV2.1 channels (P < 0.01, Mann-Whitney U-test), as found for maximal Ca2+ currents (see Figs 4C, 7A and 8A, S1 Fig). As previously reported [44], when using Ba2+ as the charge carrier, ΔF1502 only induces a significant ~11 mV left-shift on the CaV2.1 voltage-dependent activation (right panel: WT V1/2 act = -8.23 ± 1.02 mV (n = 14) versus ΔF1502 V1/2 act = -18.95 ± 1.8 mV (n = 9), P < 0.001, Mann-Whitney U-test).

(TIF)

S1 Table. Average peak inward Ca2+ current densities (pA/pF) through either WT or ΔF1502 CaV2.1 channels, elicited by 20 ms depolarizing pulses from a holding of -80 mV to the indicated voltages. Data are presented as the means ± S.E.M. For statistical comparison we used the Mann-Whitney U-test.

(DOCX)

S2 Table. Average activation kinetics of WT and ΔF1502 CaV2.1 channels at the indicated depolarizing voltages. Data are presented as the means ± S.E.M. The Mann-Whitney U-test was employed for statistical comparison.

(DOCX)

S3 Table. Average deactivation kinetics of WT and ΔF1502 CaV2.1 channels at the indicated voltages. Data are presented as the means ± S.E.M. For statistical comparison we used the Mann-Whitney U-test.

(DOCX)
Acknowledgments

We thank the patient and its family for their participation. We are grateful to Dr. J. Striessnig (University of Innsbruck, Austria) for the gift of human CACNA1A cDNA. We also thank Dr. L. Birnbaumer (National Institutes of Health, North Carolina, USA) for the gift of the cDNAs encoding rabbit $\alpha_2\delta$, and rat $\beta_3$ regulatory subunits, and Dr. Hyun Hor (Centre for Genomic Regulation, Barcelona, Spain) for his help and advice in the analyses of the Whole Exome Sequencing data.

Author Contributions

Conceived and designed the experiments: SO AM JMF-F. Performed the experiments: MIB SAS OD RR AM-G MP SO AM JMF-F. Analyzed the data: MIB SAS OD RR AM-G MP SO AM JMF-F. Wrote the paper: MIB SAS OD RR AM-G MP SO AM JMF-F. Led the study, wrote and finalized the manuscript: JMF-F.

References

1. Catterall WA. Voltage-gated calcium channels. Cold Spring Harb Perspect Biol. 2011; 3: a003947. doi: 10.1101/cshperspect.a003947 PMID: 21746798
2. Serra SA, Cuenca-León E, Llobet A, Rubio-Mocardo F, Plata C, Carreño O, et al. A mutation in the first intracellular loop of CACNA1A prevents P/Q channel modulation by SNARE proteins and lowers exocytosis. Proc Natl Acad Sci USA. 2010; 107: 1672–1677. doi: 10.1073/pnas.0908359107 PMID: 20080591
3. Westenbroek RE, Sakurai T, Elliott EM, Hell JW, Starr TV, Snutch TP, et al. Immunochemical identification and subcellular distribution of the $\alpha_{1A}$ subunits of brain calcium channels. J Neurosci. 1995; 15: 6403–6418. PMID: 7472404
4. Pineda JC, Waters RS, Foehring RC. Specificity in the interaction of HVA Ca$^{2+}$ channel types with Ca$^{2+}$-dependent AHPs and firing behavior in neocortical pyramidal neurons. J Neurophysiol. 1998; 79: 2522–2534. PMID: 9582225
5. Womack MD, Chevez C, Khodakhah K. Calcium activated potassium channels are selectively coupled to P/Q type calcium channels in cerebellar Purkinje neurons. J Neurosci. 2004; 24: 8818–8822. PMID: 15470147
6. Gao Z, Todorov B, Barrett CF, van Dorp S, Ferrari MD, van den Maagdenberg AMJM, et al. Cerebellar ataxia by enhanced CaV2.1 currents is alleviated by Ca$^{2+}$-dependent K+-channel activators in Cacna1a<sup>S218L</sup> mutant mice. J Neurosci. 2012; 32: 15533–15546. doi: 10.1523/JNEUROSCI.2454-12.2012 PMID: 23115190
7. Sutton KG, McRory JE, Guthrie H, Murphy TH, Snutch TP. P/Q-type calcium channels mediate the activity-dependent feedback of syntaxin-1A. Nature. 1999; 401: 800–804. PMID: 10548106
8. Eilers J, Plant T, Konnerth A. Localized calcium signaling and neuronal integration in cerebellar Purkinje neurons. Cell Calcium. 1996; 20: 215–226. PMID: 8889210
9. Fletcher CF, Tottene A, Lennon VA, Wilson SM, Dubel SJ, Paylor R, et al. Dystonia and cerebellar atrophy in Cacna1a null mice lacking P/Q calcium channel activity. FASEB J. 2001; 15: 1288–1290. PMID: 11344116
10. Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci. 2003; 4: 386–398. PMID: 12728266
11. Pietrobon D. Ca$_2$1 channelopathies. Pflügers Arch—Eur J Physiol. 2010; 460: 375–393.
12. Pelzer N, Stam AH, Haan J, Ferrari MD, Terwindt GM. Familial and sporadic hemiplegic migraine: diagnosis and treatment. Curr Treat Options Neurol. 2013; 15: 13–27. doi: 10.1007/s11940-012-0208-3 PMID: 23203776
13. Serra SA, Fernández-Castillo N, Macaya A, Cormand B, Valverde MA, Fernández-Fernández JM. The Hemiplegic Migraine associated Y1245C mutation in CACNA1A results in a gain of channel function due to its effect on the voltage sensor and G-protein mediated inhibition. Pflügers Arch—Eur J Physiol. 2009; 458: 489–502.
14. Carreño O, Corominas R, Serra SA, Sintas C, Fernández-Castillo N, Vila-Pueyo M, et al. Screening of CACNA1A and ATP1A2 genes in hemiplegic migraine: clinical, genetic, and functional studies. Mol Genet & Genomic Med. 2013; 1: 206–222.

15. Vecchia D, Tottene A, van den Maagdenberg AMJM, Pietrobon D. Mechanism underlying unaltered cortical inhibitory synaptic transmission in contrast with enhanced excitatory transmission in CaV2.1 knockin migraine mice. Neurobiol Dis. 2014; 69: 225–234. doi: 10.1016/j.nbd.2014.05.035 PMID: 24907493

16. van den Maagdenberg AMJM, Pietrobon D, Pizzorusso T, Kaja S, Broos LA, Cesetti T, et al. A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron. 2004; 41: 701–710. PMID: 15003170

17. Tottene A, Conti R, Fabbro A, Vecchia D, Shapovalova M, Santello M, et al. Enhanced excitatory transmission at cortical synapses as the basis for facilitated spreading depression in CaV2.1 knockin mice. Neuron. 2009; 61: 762–773. doi: 10.1016/j.neuron.2009.01.027 PMID: 19285472

18. Di Guilmi MN, Wang T, Inchauspe CG, Forsythe ID, Ferrari MD, van den Maagdenberg AMJM, et al. Reduced voltage sensitivity of actin binding domain of CaV2.1 channels in a mouse model of familial hemiplegic migraine are due to increased basal [Ca2+]i. J Neurosci. 2014; 34: 7047–7058. doi: 10.1523/JNEUROSCI.2526-13.2014 PMID: 24849341

19. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med. 2002; 8: 136–142. PMID: 11821897

20. Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol. 2013; 75: 365–391. doi: 10.1146/annurev-physiol-030212-183717 PMID: 23190076

21. Cuenca-León E, Banchs I, Serra SA, Latorre P, Fernández-Castillo N, Corominas R, et al. Late-Onset Episodic Ataxia Type 2 associated with a novel loss-of-function mutation in the CACNA1A gene. J Neurol Sci. 2009; 28: 10–14.

22. Strupp M, Zwergal A, Brandt T. Episodic ataxia type 2. Neurotherapeutics. 2007; 4: 267–273. PMID: 17395137

23. Scoggan KA, Friedman JH, Bulman DE. CACNA1A mutation in a EA-2 patient responsive to acetazolamide and valproic acid. Can J Neurol Sci. 2006; 33: 68–72. PMID: 16583725

24. Rajakulendran S, Graves TD, Labrum RW, Kotzadimitriou D, Eunson L, Davis MB, et al. Genetic and functional characterisation of the P/Q calcium channel in episodic ataxia with epilepsy. J Physiol. 2010; 588: 1905–1913. doi: 10.1113/jphysiol.2009.186437 PMID: 20156848

25. Imbrici P, Jaffe SL, Eunson LH, Davies NP, Hord C, Robertson R, et al. Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia. Brain. 2004; 127: 2682–2692. PMID: 15483044

26. Vila-Pueyo M, Gené GG, Flotats-Bastardes M, Elorza X, Sintas C, Valverde MA, et al. A loss-of-function CACNA1A mutation causing benign paroxysmal torticollis of infancy Eur J Paediatr Neurol. 2014; 18: 430–433. doi: 10.1016/j.ejpn.2013.12.011 PMID: 24445160

27. Mori Y, Wakamori M, Oda S, Fletcher CF, Sekiguchi N, Mori E, et al. Reduced voltage sensitivity of activation of P/Q-type Ca2+ channels is associated with the ataxic mouse mutation Rolling Nagoya (tgαCaV2.1). J Neurosci. 2000; 20: 5654–5662. PMID: 10908603

28. Imbrici P, Jaffe SL, Eunson LH, Davies NP, Herd C, Robertson R, et al. Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia. Brain. 2004; 127: 2682–2692. PMID: 15483044

29. Spacey SD, Hildebrand ME, Materek LA, Bird TD, Snutch TP. Functional implications of a novel EA2 mutation in the P/Q-type calcium channel. Ann Neurol. 2004; 56: 213–220. PMID: 15293273

30. Wan J, Khanna R, Sandusky M, Papazian DM, Jen JC, Baloh RW. CACNA1A mutations causing episodic and progressive ataxia alter channel trafficking and kinetics. Neurology. 2005; 64: 2090–2097. PMID: 15985579

31. Wappl E, Koschak A, Poteser M, Sinnegger MJ, Walter D, Eberhart A, et al. Functional consequences of P/Q-type Ca2+ channel CaV2.1 missense mutations associated with episodic ataxia type 2 and progressive ataxia. J Biol Chem. 2002; 277: 6960–6966. PMID: 11742003

32. Ricci C, Di Lorenzo C, Greco GS, Rengo C, Cardinale A, Racanelli M, et al. Early-onset progressive ataxia associated with the first CACNA1A mutation identified within the I-II loop. J Neurol Sci. 2007; 254: 69–71. PMID: 17292920

33. Rose SJ, Kriener LH, Heinzer AK, Fan X, Raine RS, van den Maagdenberg AMJM, et al. The first knockin mouse model of episodic ataxia type 2. Exp Neurol. 2014; 261C: 553–562.

34. Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the α1A-voltage-dependent calcium channel. Nature Genet. 1997; 15: 62–69. PMID: 8988170
35. Watase K, Barrett CF, Miyazaki T, Ishiguro T, Ishikawa K, Hu Y, et al. Spinocerebellar ataxia type 6 knock in mice develop a progressive neuronal dysfunction with age-dependent accumulation of mutant Cav2.1 channels. Proc Natl Acad Sci USA. 2008; 105: 11987–11992. doi:10.1073/pnas.0804350105 PMID: 18687887

36. Fitzsimons RB, Wolfenden WH. Migraine coma: meningitic migraine with cerebral oedema associated with a new form of autosomal dominant cerebellar ataxia. Brain. 1985; 108: 555–577. PMID:4041774

37. Kors EE, Terwindt GM, Vermeulen FL, Fitzsimons RB, Jardine PE, Heywood P, et al. Delayed cerebral edema and fatal coma after minor head trauma: role of the CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine. Ann Neurol. 2001; 49: 753–760. PMID: 11409427

38. Terwindt GM, Ophoff RA, Haan J, Vergouwe MN, van Eijk R, Frants RR, et al. Variable clinical expression of mutations in the P/Q-type calcium channel gene and relationship with familial hemiplegic migraine. Dutch Migraine Genetics Research Group. Neurology. 1998; 50: 1105–1110. PMID: 9566402

39. Ducros A, Denier C, Joutel A, Vahedi K, Michel A, Darcel F, et al. Recurrence of the T666M calcium channel CACNA1A gene mutation in familial hemiplegic migraine with progressive cerebellar ataxia. Am J Hum Genet. 1999; 64:89–98. PMID: 9915947

40. Wada T, Kobayashi N, Takahashi Y, Aoki T, Watanabe T, Saitoh S. Wide clinical variability in a family with a CACNA1A T666M mutation. Pediatr Neurol. 2002; 26: 47–50. PMID: 11814735

41. Blumkin L, Michelson M, Leshinsky-Silver E, Kivity S, Lev D, Lerman-Sagie T. Congenital ataxia, mental retardation, and dyskinesia associated with a novel CACNA1A mutation. J Child Neurol. 2010; 25:892–7. doi: 10.1177/0883073809351316

42. Knierim E, Leisle L, Wagner C, Wescshe B, Lucke B, Bohner G, et al. Recurrent stroke due to a novel voltage sensor mutation in Cav2.1 responds to verapamil. Stroke. 2011; 42: e14–7. doi: 10.1161/STROKEAHA.110.600023

43. Naik S, Pohl K, Malik M, Siddiqui A, Josifova D. Early-onset cerebellar atrophy associated with mutation in the CACNA1A gene. Pediatr Neurol. 2011; 45: 328–330. doi: 10.1016/j.pediatrneurol.2011.08.002

44. García-Segarra N, Gautschi I, Mittaz-Crettol L, Kallay Zetchi C, Al-Qusairi L, Van Bemmelen MX, et al. Congenital ataxia and hemiplegic migraine with cerebral edema associated with a novel gain of function mutation in the calcium channel CACNA1A. J Neurol Sci. 2014; 342: 69–78. doi: 10.1016/j.jns.2014.04.027

45. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011; 43: 491–498. doi: 10.1038/ng.1708

46. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv 2013; 00 (00): 1–3.

47. Ossowski S, Schneeberger K, Clark RM, Lanz C, Warthmann N, Weigel D. Sequencing of natural strains of Arabidopsis thaliana with short reads. Genome Res. 2008; 18: 2024–33. doi: 10.1101/gr.080200.108

48. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38: e164. doi: 10.1093/nar/gkq603

49. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003; 31: 3812–3814. PMID: 12824425

50. Gonzalez-Perez A, Lopez-Bigas N. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum Genet. 2011; 88: 440–449. doi: 10.1016/j.ajhg.2011.03.004

51. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014; 46: 310–315. doi: 10.1038/ng.2892

52. Margulies EH, Blanchette M, NSC Comparative Sequencing Program, Haussler D,Green ED. Identification and characterization of multi-species conserved sequences, Genome Res. 2003; 13: 2507–2518. PMID: 14656959

53. TranchoYent LC, Barriot R, Yu S, Van Vooren S, Van Loo P, Coessens B, et al. ENDEAVOUR update: a web resource for gene prioritization in multiple species. Nucleic Acids Res. 2008; 36(Web Server issue): W377–384. doi: 10.1093/nar/gkn325

PMID: 18508807
55. Hamosh AA, Scott F, Amberger JS, Bocchini CA, McKusick VA. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 2005; 33(Database issue): D514–517. PMID: 15608251
56. Kaplan JC, Hamroun D. The 2014 version of the gene table of monogenic neuromuscular disorders (nuclear genome). Neuromuscul Disord. 2013; 23: 1081–1111. PMID: 24446552
57. Pattillo JM, Artim DE, Simples JE Jr, Meriney SD. Variations in onset of action potential broadening: effects on calcium current studied in chick ciliary ganglion neurones. J Physiol. 1999; 514: 719–728. PMID: 9882744
58. Oelstrom K, Goldschen-Ohm MP, Holmgren M, Chanda B. Evolutionarily conserved intracellular gate of voltage-dependent sodium channels. Nat Commun. 2014; 5: 3420. doi: 10.1038/ncomms4420 PMID: 24619022
59. Zhong H, Yokoyama CT, Scheuer T, Catterall WA. Reciprocal regulation of P/Q type Ca2+ channels by SNAP-25, syntaxin and synaptotagmin. Nat Neurosci. 1999; 2: 939–941. PMID: 10526329
60. Kraus RL, Sinnegger MJ, Koschak A, Glossmann H, Stenirri S, Carrera P, et al. Three new familial hemiplegic migraine mutants affect P/Q-type Ca2+ channel kinetics. J Biol Chem. 2000; 275: 9239–9243. PMID: 10734061
61. Pietrobon D. Familial hemiplegic migraine. Neurotherapeutics 2007; 4: 274–284. PMID: 17395138
62. Fioretti B, Catacuzzeno L, Sforna L, Gerke-Duncan MB, van den Maagdenberg AMJM, Franciolini F, et al. Trigeminal ganglion neuron subtype-specific alterations of CaV2.1 calcium current and excitability in a CaCna1a mouse model of migraine. J Physiol. 2011; 589: 5879–5895. doi: 10.1113/jphysiol.2011.220533 PMID: 22005682
63. van den Maagdenberg AMJM, Pizzorusso T, Kaja S, Terpolilli N, Shapovalova M, Hoebeek FE, et al. High cortical spreading depression susceptibility and migraine-associated symptoms in CaV2.1 S218L mice. Ann Neurol. 2010; 67: 85–98. doi: 10.1002/ana.21815 PMID: 20186955
64. Kasumu A, Bezprozvanny I. Deranged calcium signaling in Purkinje cells and pathogenesis in spinocerebellar ataxia 2 (SCA2) and other ataxias. Cerebellum. 2012; 11: 630–9. doi: 10.1007/s12311-010-0182-9 PMID: 20480274
65. Turkmen S, Guo G, Garshasbi M, Hoffmann K, Aleshahal AJ, Mischung C, et al. CA8 mutations cause a novel syndrome characterized by ataxia and mild mental retardation with predisposition to quadrapedal gait. PLoS Genet. 2009; 5(5): e1000487. doi: 10.1371/journal.pgen.1000487 PMID: 19461874
66. Kaya N, Aldhalaa H, Al-Younes B, Colak D, Shuaib T, Al-Mohaileb F, et al. Phenotypical spectrum of cerebellar ataxia associated with a novel mutation in the CA8 gene, encoding carbonic anhydrase (CA) VIII. Am J Med Genet Part B. 2011; 156: 826–834.
67. Hirota J, Ando H, Hamada K, Mikoshiba K. Carbonic anhydrase-related protein is a novel binding protein for inositol 1,4,5-trisphosphate receptor type 1. Biochem J. 2003; 372: 435–441. PMID: 12611586
68. Sotelo C, Hillman DE, Zamora AJ, Llanas R. Climbing fiber deafferentation: its action on Purkinje cell dendritic spines. Brain Res. 1975; 98: 574–581. PMID: 1182538
69. Bravin M, Morando L, Vercelli A, Rossi F, Strata P. Control of spine formation by electrical activity in the adult rat cerebellum. Proc Natl Acad Sci USA. 1999; 96:1704–1709. PMID: 9990068
70. Jiao Y, Yan J, Zhao Y, Donahue LR, Beamer WG, et al. Carbonic anhydrase-related protein VIII deficiency is associated with a distinctive lifelong gait disorder in waddles mice. Genetics. 2005; 171: 1239–1246. PMID: 16118194
71. Aspatwar A, Tolvanen MEE, Jokitalo E, Parikka M, Orttutay C, Harjula S-KE, et al. Abnormal cerebellar development and ataxia in CARP VIII morphant zebrafish. Hum Mol Genet. 2013; 22: 417–432. doi: 10.1038/hmg.dds.438 PMID: 23087022
77. Zanni G, Calì T, Kalscheuer VM, Ottolini D, Barresi S, Lebrun N, et al. Mutation of plasma membrane Ca\textsuperscript{2+} ATPase isoform 3 in a family with X-linked congenital cerebellar ataxia impairs Ca\textsuperscript{2+} homeostasis. Proc Natl Acad Sci USA. 2012; 109: 14514–14519. doi:10.1073/pnas.1207488109 PMID: 22912398

78. Inagaki A, Frank CA, Usachev YM, Benveniste M, Lee A. Pharmacological correction of gating defects in the voltage-gated Ca\textsubscript{v}2.1 Ca\textsuperscript{2+} channel due to a Familial Hemiplegic Migraine mutation. Neuron. 2014; 81: 91–102. doi: 10.1016/j.neuron.2013.10.056 PMID: 24411734

79. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera: a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25: 1605–12. PMID: 15264254